http://orcid.org/0000-0003-0410-5814
Figures
Abstract
Articular cartilage has poor healing ability and cartilage injuries often evolve to osteoarthritis. Cell-based strategies aiming to engineer cartilaginous tissue through the combination of biocompatible scaffolds and articular chondrocytes represent an alternative to standard surgical techniques. In this context, perfusion bioreactors have been introduced to enhance cellular access to oxygen and nutrients, hence overcoming the limitations of static culture and improving matrix deposition. Here, we combined an optimized cocktail of soluble factors, the BIT (BMP-2, Insulin, Thyroxin), and clinical-grade collagen sponges with a bidirectional perfusion bioreactor, namely the oscillating perfusion bioreactor (OPB), to engineer in vitro articular cartilage by human articular chondrocytes (HACs) obtained from osteoarthritic patients. After amplification, HACs were seeded and cultivated in collagen sponges either in static or dynamic conditions. Chondrocyte phenotype and the nature of the matrix synthesized by HACs were assessed using western blotting and immunohistochemistry analyses. Finally, the stability of the cartilaginous tissue produced by HACs was evaluated in vivo by subcutaneous implantation in nude mice. Our results showed that perfusion improved the distribution and quality of cartilaginous matrix deposited within the sponges, compared to static conditions. Specifically, dynamic culture in the OPB, in combination with the BIT cocktail, resulted in the homogeneous production of extracellular matrix rich in type II collagen. Remarkably, the production of type I collagen, a marker of fibrous tissues, was also inhibited, indicating that the association of the OPB with the BIT cocktail limits fibrocartilage formation, favoring the reconstruction of hyaline cartilage.
Citation: Mayer N, Lopa S, Talò G, Lovati AB, Pasdeloup M, Riboldi SA, et al. (2016) Interstitial Perfusion Culture with Specific Soluble Factors Inhibits Type I Collagen Production from Human Osteoarthritic Chondrocytes in Clinical-Grade Collagen Sponges. PLoS ONE 11(9): e0161479. https://doi.org/10.1371/journal.pone.0161479
Editor: Florence Ruggiero, Ecole normale superieure de Lyon, FRANCE
Received: May 17, 2016; Accepted: August 6, 2016; Published: September 1, 2016
Copyright: © 2016 Mayer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: NM held a CMIRA Explora’ doc 2011 fellowship from the Rhône-Alpes Region (en.rhonealpes.fr). This work was financially supported by the French National Centre for Scientific Research (CNRS, www.cnrs.fr), the Université Claude Bernard Lyon 1 (www.univ-lyon1.fr) and by the Italian Ministry of Health (www.salute.gov.it). The CNRS provided support in the form of salary for FMG and MP and the CNRS and the Université Claude Bernard Lyon 1 provided support in the form of research materials. The Italian Ministry of Health provided support in the form of salaries for SL, GT, ABL, and MM and of research materials. These funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bioengineering Laboratories S.r.l. provided support in the form of salary for SR, but it did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the ‘author contributions’ section.
Competing interests: MM is one of the inventors of the patent #WO2008098165A2 (also published as #EP2134830A2, #US9217129, #US20100297233, #WO2008098165A3, #WO2008098165A9) issued by USPTO. This patent has been licensed to SKE S.r.l. for product development and scientific validation. MM does not hold any share in SKE S.r.l. SR and her employer Bioengineering Laboratories S.r.l. are co-founders and share-holders of SKE S.r.l.; SR is also board member of SKE S.r.l. The OPB patent and its licensing, as well as the commercial affiliations of SR, do not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors have no competing interests to declare.
Introduction
The incidence of degenerative and traumatic cartilage lesions is increasing due to the global population ageing and to the more intensive practice of sport activities. Articular cartilage is an avascular tissue with poor intrinsic healing ability. Consequently, cartilage injuries are irreversible and often evolve to osteoarthritis (OA), causing pain and disability. Several surgical approaches, such as mosaicplasty or microfractures, have been developed to repair damaged cartilage to avoid or at least delay joint replacement. However, these treatments remain unsatisfactory due to the occurrence of type I collagen-rich fibrocartilage [1, 2] which has inferior biomechanical properties than type II collagen-rich hyaline cartilage.
Articular cartilage, containing a single type of resident cells, is a good candidate for cell-based therapies and tissue engineering approaches. Autologous chondrocyte implantation (ACI) [3] is now performed worldwide to treat articular cartilage focal lesions. In this procedure, human articular chondrocytes (HACs) are isolated from a small cartilage biopsy and amplified in vitro, before being re-implanted back in the patient. However, during in vitro expansion, HACs undergo a dedifferentiation process characterized by the loss of type II collagen expression in favor of type I collagen. This process is a major determinant in the formation of type I collagen-rich fibrocartilage following ACI [4–6]. Hence, to improve ACI clinical outcomes, research has been focused on the use of biomaterials and growth factors able to drive HAC redifferentiation and broaden ACI application to larger defects, such as early OA lesions.
We have previously investigated the reconstruction of cartilaginous matrix by HACs in collagen sponges [7]. We used a combination of soluble growth factors during HAC expansion (fibroblast growth factor (FGF)-2 and insulin, designated FI) and 3D culture in collagen sponges (bone morphogenetic protein (BMP)-2, insulin, and thyroxin T3, designated BIT), that had been optimized for human auricular chondrocytes in collagen gels [8]. We found that the FI-BIT combination allows high HAC proliferation and cartilaginous extracellular matrix (ECM) synthesis in collagen sponges [7]. However, we also showed that ECM was restricted to the scaffold periphery, suggesting impaired nutrition and growth factor delivery in the sponge core.
Perfusion bioreactors have been shown to enhance cell access to oxygen and nutrients and the homogeneity of neo-synthesized ECM in 3D scaffolds [9, 10]. We have previously shown that the association of dynamic culture in an oscillating perfusion bioreactor, namely the OPB [11], with specific growth factors enhanced cell differentiation in tissue-engineered cardiac grafts, indicating that perfusion increases growth factor efficacy [12]. Furthermore, we have used the OPB to engineer cartilaginous constructs, demonstrating increased total collagen content and improved matrix deposition upon dynamic culture [13].
These results prompted us to investigate the combination of perfusion culture in the OPB with the aforementioned protocol of amplification/redifferentiation [7] for the culture of osteoarthritic HACs in clinical-grade collagen sponges. Special attention was given to the neo-synthesized matrix through the analysis of type I and type II collagen deposition.
Materials and Methods
Cell isolation and expansion
HACs were isolated from macroscopically non-fibrillated zones of osteoarthritic joints from 10 donors (age range: 50–74) undergoing total hip replacement. The study was carried out in accordance with local ethics guidelines and with the approval of the Scientific Directorate of the IRCCS Galeazzi Orthopaedic Institute. Biopsies were collected during surgery as anonymous waste material after donors’ written informed consent. Chondrocytes were extracted through sequential enzymatic digestion with 0.2% trypsin (Sigma) and 0.15% bacterial collagenase A (Roche Applied Science), as previously described [14]. HACs were then seeded at 0.8×104 cells/cm2 in complete medium composed of HG-DMEM/Ham’s F12 (mixed 1:1, Gibco) supplemented with 10% newborn calf serum (NCS, Hyclone), 50 μg/mL streptomycin (Panpharma) and 2 μg/mL amphotericin B (Bristol Myers Squibb). At this stage, cells were designated P0. After 36 h (P0-36h), complete medium was refreshed and further supplemented with 5 ng/mL FGF-2 (R&D Systems) and 5 μg/mL insulin (Umuline rapide, Lilly), namely the FI cocktail [7]. FI-supplemented complete medium was replaced three times a week. At about 90% confluence, cells were trypsinized and replated at the same density for another passage (P1). After each trypsinization, live cells were counted with Trypan blue exclusion. The entire monolayer expansion phase lasted 25–28 days for all the donors.
Preparation of the collagen scaffolds
Redifferentiation experiments were performed in collagen sponges purchased by Symatèse Biomatériaux. These scaffolds are composed of native (90–95%) type I collagen and (5–10%) type III collagen and are prepared from calf skin. During the manufacturing process, the sponges were cross-linked by glutaraldehyde and sterilized with 25 kGy β-radiation to increase their stability (pore size ~100 μm, Symatèse Biomatériaux) [7]. The collagen sponges were then sized in our laboratory with a skin biopsy punch (0.1 cm3, 8 mm diameter x 2 mm height).
Static culture
Passaged P1 HACs were suspended in complete medium and seeded into the sponges at 1.3×107 cells/cm3 (1.3×106 cells/sponge) as previously described [7]. The sponges were then placed in 6-well plates and incubated at 37°C for 2h. Complete medium supplemented with 50 μg/mL 2-phospho-L-ascorbic acid (Fluka) was added. After 48 h, medium was replaced with fresh complete medium containing 50 μg/mL 2-phospho-L-ascorbic acid supplemented or not with 200 ng/mL recombinant human BMP-2 (dibotermin-alpha, drug form of BMP-2, InductOs kit, Wyeth), 5 μg/mL insulin, and 100 nM thyroxin T3 (Sigma), namely the BIT cocktail [7]. Medium was replaced twice a week over a culture period of 21 days.
Dynamic culture in the OPB
The OPB was used as previously described [13]. Each collagen sponge was press-fitted into a scaffold holder that was then inserted in a chamber attached to a loop of gas-permeable silicone rubber tube (6.35 mm perfusion diameter, 1/32 inch wall thickness, Cole Parmer). Eighteen closed-loop chambers were mounted on 12.5 cm-diameter discs and then on an incubator-compatible motorized frame oscillating the chambers around their central axis (Fig 1). Interstitial fluid flow was ensured fixing the construct within the scaffold holder to avoid fluid flow around the construct.
(a) The tissue culture unit is a closed loop of gas-permeable silicone tubing connected to a chamber (asterisk). A single collagen sponges is fixed within a scaffold holder inserted in the chamber to avoid fluid flow around the construct. (b) Eighteen independent closed-loop chambers are mounted on a motorized frame oscillating the chambers around their central axis in a pendulum-like motion. (c) Time sequences of the two perfusion programs used with the OPB.
Passaged P1 HACs were seeded at 1.3×107 cells/cm3 (1.3×106 cells/sponge). Specifically, 3 mL of cell suspension prepared in complete medium supplemented with 50 μg/mL 2-phospho-L-ascorbic acid were added to 7 mL of the same medium in each OPB chamber. The flow velocity was 1000 μm/s for 24 h, then 300 μm/s for additional 24 h. After 48 h, the medium in each chamber was replaced with 6 mL of complete medium containing 50 μg/mL 2-phospho-L-ascorbic acid, supplemented or not with BIT. Medium was replaced twice a week over a culture period of 21 days.
After cell seeding, two perfusion programs were applied (Fig 1c): in program 1, we applied a velocity of 100 μm/s during the whole culture. In program 2, we first applied a velocity of 5 μm/s for 72 h. Then, velocity was progressively increased up to 20 μm/s in 7 days and cycles of velocity variations were applied for the last 9 days (5 μm/s for 8 h followed by a progressive increase to 20 μm/s in 16 h).
Gene expression analysis
Total RNA was isolated using the NucleoSpin RNA II kit (Macherey-Nagel). 100 ng RNA per sample were used for reverse transcription, as previously described [15]. Real-time PCR was performed in a Rotor-Gene Q cycler (Qiagen) using 10 μL Fast Start Universal SYBR Green Master (Roche), 4 μL cDNA (1:5dilution), 300 nM primers, and 4 μL water. Cycling conditions consisted of a denaturation step at 95°C for 2 min, 40 cycles of 95°C for 15 s and annealing and extension at 60°C for 30 s. Primer sequences were derived from literature [16]: COL2A1 F: GGCAATAGCAGGTTCACGTACA, R: CGATAACAGTCTTGCCCCACTT; COL1A1 F: CAGCCGCTTCACCTACAGC, R: TTTTGTATTCAATCACTGTCTTGCC; GAPDH F: ATGGGGAAGGTGAAGGTCG, R: TAAAAGCAGCCCTGGTGACC. Fluorescence thresholds (Ct) were determined by the software (amplification efficiency range: 90%-110%). GAPDH Ct value was subtracted from the target Ct value to obtain ΔCt. Expression level was then calculated as 2-ΔCt and expressed as the mean of duplicate samples.
Antibodies
Antibodies were diluted in Tris-Buffered Saline-Tween (TBS-T) with 5% Blotting-Grade Blocker (BioRad) for Western Blot (WB) or in PBS containing 3% Bovine Serum Albumin (PBS-BSA) for immunohistochemistry (IHC). Polyclonal rabbit antibodies to human type II collagen (Ref 20211) were kindly provided by D.J. Hartmann [17] and used at 1:5000 for WB or 1:500 for IHC. Polyclonal rabbit antibodies to human type I collagen (Novotec, Ref. 20111) and human actin (Sigma, Ref. A5060) were used respectively at 1:5000 and 1:1000 for WB and the type I collagen antibodies were used at 1:1000 for IHC. Alkaline phosphatase-conjugated anti-rabbit or anti-mouse IgG (BioRad) and horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibodies (Cell Signaling Technology) were used respectively at 1:5000 and 1:2000 for WB. For IHC, anti-rabbit (HRP)-linked antibodies (used undiluted) were from Dako (cat. K4002).
Western Blot analysis
After 21 days of in vitro culture, collagen sponges were frozen in liquid nitrogen. After thawing, sponges were rinsed with PBS containing 2 mM EDTA and 0.2 mM phenylmethanesulfonylfluoride (PMSF), refrozen, powdered with a mortar and pestle, and boiled in Laemmli buffer for 5 minutes, as previously described [7]. For WB, equivalent sample volumes were separated by SDS-PAGE (4–12% gradient gels) and transferred to a polyvinylidene difluoride membrane (PVDF, Millipore) in CAPS buffer (N-cyclohexyl-3-aminopropanesulfonic acid, Sigma) supplemented with 7.5% methanol (90 min, 65V). After transfer, membranes were saturated in TBS-T containing 5% blocker for 1h at r.t., probed with primary antibodies either 1h at r.t. or overnight at 4°C, washed with TBS-T and incubated for 45 min at r.t. with secondary antibodies: alkaline phosphatase-conjugated IgG to detect type I and type II collagen or with HRP-conjugated IgG to detect actin. After washing, bound antibodies were detected on X-ray films using Immun-star AP or HRP chemiluminescent substrate (BioRad). Membranes were re-probed with antibodies after striping (Re-Blot Plus Strong, Chemicon).
For densitometric analysis, exposure times of X-ray films were optimized. The developed X-ray films were scanned and band intensities were determined using ImageJ software. The given values represent total collagen, namely the unprocessed chains (pro), the processing intermediates of the procollagen containing the aminopropeptide (pN) or the carboxypropeptide (pC) and the mature collagen chains, normalized to actin.
Histological and immunohistochemical analysis
Histological analysis of collagen sponges was performed after 7, 14, and 21 days. Samples were rinsed in PBS and fixed for 24 h with 4% neutral-buffered formalin. After dehydration, samples were paraffin-embedded, sectioned at 5 μm, and stained with Mayer's hematoxylin and eosin (HE). To detect sulfated proteoglycans, sections were stained with Safranin-O in 0.1 M sodium acetate (pH 7.4) for 10 min.
For IHC, deparaffinized and rehydrated sections were digested with 0.5% hyaluronidase diluted in PBS-BSA for 1 h at r.t. to unmask the antigenic sites. Incubation with primary antibodies was carried out in PBS-BSA overnight at 4°C. After washing with PBS and PBS with 0.2% Tween-20, endogenous peroxidase activity was inhibited by treatment with 0.5% aqueous H2O2 in PBS-BSA. Then, HRP-conjugated secondary antibodies were applied for 45 min at r.t. Finally, sections were revealed with diaminobenzidine and counterstained with HE. Images were acquired with a DM750 microscope (Leica) with an integrated color camera (ICC50 HD) using the Las Ez software (Leica).
In vivo subcutaneous implantation
After 21 days of in vitro static or dynamic culture, the constructs were subcutaneously implanted in the back of athymic mice to evaluate the maintenance of the redifferentiated phenotype of HACs and the stability of the neo-synthesized matrix, as previously reported by several studies [18–20]. The in vivo study was approved by the Mario Negri Institute for Pharmacological Research (IRFMN) Animal Care and Use Committee (IACUC). Animals and their care were handled in compliance with institutional guidelines, as defined in national (Law 116/92, Authorization n.19/2008-A, Italian Ministry of Health, March 6, 2008) and international laws and policies (EEC Council Directive 86/609, OJ L 358. 1, December 12, 1987; Standards for the Care and Use of Laboratory Animals-UCLA, U.S. National Research Council, Statement of Compliance A5023-01, November 6, 1998). The animals were regularly monitored by a certified veterinarian responsible for general animal health and welfare supervision, experimental protocols and procedure revision. All surgeries were performed under general anesthesia and all efforts were made to minimize suffering.
Six female athymic mice (six weeks old) were obtained from Harlan® and maintained in the Animal Care Facilities of IRFMN, under pathogen-free conditions with food and water ad libitum. Surgical procedures were performed as described in previous studies [21, 22]. Briefly, animals were anesthetized by intraperitoneal injection of ketamine chloride (80 mg/kg, Imalgene, Merial) and medetomidine hydrochloride (1 mg/kg, Domitor, Pfizer) and surgeries were performed under a laminar flow hood in sterile conditions. Four unconnected subcutaneous pockets were created on the dorsum of each mouse by blunt dissection through cranial and caudal skin incisions. One construct was inserted in each pocket, then the skin was sutured with #4–0 Monocryl thread (Ethicon). Constructs from 3 donors were implanted (donors 8–10). For each donor, constructs cultured in static and dynamic conditions were implanted in the same mouse. After 6 weeks, the mice were euthanized by CO2 inhalation. At explantation, all constructs were dissected from the mice and processed for IHC.
Statistical analysis
Quantitative differences in collagen production between experimental groups were analyzed using the non-parametric Mann-Whitney U-test. A p-value p < 0.05 was considered significant. The number of HAC donors used for each experiment/analysis is noted in the figure legends as “n”.
Results
Topography of the neo-synthesized matrix
After isolation, HACs were amplified in monolayer in the presence of FI. During this step, HACs lost their spherical shape and acquired a fibroblastic shape (Fig 2a). A marked decrease in type II collagen in favor of type I collagen expression was also observed during the amplification step (Fig 2b), indicating that HACs underwent dedifferentiation.
(a) Representative phase-contrast micrographs showing changes in cell morphology during HAC expansion in monolayer (scale bars 50 μm). (b) Transcriptional levels of type I and type II collagen measured by Real-time PCR. Data were normalized on GAPDH using the 2-ΔCt method, expressed relatively to data obtained for P0 HACs36 hours after isolation (P0-36h, reference value = 1) and reported as single data points with mean in the dot plots (n = 10, a: p < 0.05, significant effects versus P0-36h HACs; b: p < 0.05, significant effect versus P0 HACs).
The dedifferentiated HACs were cultured in collagen sponges for 21 days in either static or dynamic conditions. In the absence of BIT, no matrix deposition was evidenced in both conditions (Fig 3a). When BIT was added in static conditions, peripheral deposition of ECM was observed, but no matrix was detected in the sponge core. Conversely, in the presence of BIT under perfusion, we observed that neo-synthesized ECM was homogeneously distributed throughout the scaffold. Besides, Safranin-O staining revealed a superior presence of sulfated proteoglycans in the core of dynamic samples cultured with BIT compared to static samples (Fig 3a, inserts). Additionally, a close look into the sponge core indicated that dynamic conditions improved cell distribution throughout the sponges, compared to static conditions (Fig 3b).
(a) Representative low-magnification pictures showing cell and ECM distribution in collagen sponges cultured for 21 days in static or dynamic conditions (program 1, n = 4) in the absence (CTR) or in the presence of BIT (HE staining, scale bars 100 μm). Inserts in the left low corner show the Safranin O staining in the scaffold core (scale bars 10 μm). (b) High-magnification pictures showing cell and matrix distribution in the scaffold core (HE staining, scale bars 100 μm).
Characterization of the neo-synthesized matrix
To further characterize the ECM produced by HACs under the stimulation of BIT, we performed IHC for type II and type I collagen, markers of hyaline cartilage and fibrocartilage, respectively. To evaluate the impact of perfusion on HACs in the scaffold core, photographs of this region were taken at 21 days. In static conditions, HACs appeared isolated and exhibited a fibroblastic shape (Fig 4). By contrast, in dynamic conditions under either program 1 or 2, HACs exhibited a round morphology, typical of well-differentiated chondrocytes (Fig 4). In dynamic constructs, we observed zones with several HACs surrounded by neo-synthesized matrix immunoreactive for both type II and type I collagen (Fig 4).
HACs were cultured for 21 days within collagen sponges in static or dynamic conditions using either program 1 (n = 4) or program 2 (n = 6) in the presence of BIT. Representative pictures show parallel sections of the scaffold core stained for type II and type I collagen by IHC (scale bars 10 μm).
Interestingly, in perfused sponges we found type II collagen in cell cytoplasm, whereas type I collagen was detected in ECM but not in cell cytoplasm (Fig 5). Conversely, sponges in static conditions displayed type I collagen in both ECM and cell cytoplasm (Fig 5). Similar results were obtained when using program 1 and 2, indicating that the two perfusion programs resulted in equivalent patterns of type I and type II collagen expression.
Representative high magnification observations of HACs cultured for 21 days in static or dynamic conditions using either program 1 (n = 4) or program 2 (n = 6) in the presence of BIT (scale bars 10 μm). N: nucleus. The dotted lines indicate the cell border.
Perfusion culture hampers type I collagen production
To quantitatively determine the biochemical composition of the neo-synthesized matrix, WB analysis were performed on sponges cultured in static or dynamic conditions in the presence of BIT. Observation of total collagen production revealed that type II collagen, the typical component of the cartilage collagen fibrils, was synthesized in both conditions, whereas a lower amount of type I collagen was detected in the sponges cultured under perfusion (Fig 6a). The densitometric analysis of WB data confirmed a significantly lower production of type I collagen and showed a positive trend for type II/type I collagen ratio in sponges cultured in dynamic conditions (Fig 6b). WB analysis revealed that type II collagen was present as unprocessed, intermediate, and mature chains in sponges cultured in both static and dynamic conditions (Fig 6). In addition, in both conditions the presence of covalently cross-linked dimers of type II collagen indicated their possible organization into a fibrillar network. The presence of unprocessed, intermediate, and mature chains of type I collagen was clearly detected only in static constructs. Indeed, in sponges cultured under perfusion the presence of type I collagen was mainly restricted to mature chains, suggesting that HACs were no longer actively producing type I collagen. This result was in full concordance with IHC results showing that type II, but not type I collagen, was present in cell cytoplasm at the end of the perfusion culture.
(a) Representative WB analysis of type II and type I collagen after 21 days in static or dynamic conditions (program 2) in the presence of BIT. The positions of mature collagen chains (mature), unprocessed (pro) or processing intermediates of the procollagen containing the aminopropetide (pN) or the carboxypropetide (pC) are indicated. The upper band represents dimers (β) of collagen molecules. Actin bands are shown as a control for equivalent loading of the extracts. Please note that because type I collagen was more abundantly produced in static conditions, bands are smeared. (b) Quantification of type I collagen and of type II/type I collagen ratio through the densitometric analysis of WB data. Total type I and total type II collagen (i.e. the unprocessed chains, the processing intermediates of the procollagen, and the mature collagen chains) were normalized to actin. The values given in the dot plots represent single data points with mean (n = 6, a: p < 0.05).
Similar profiles of collagen synthesis were obtained when the perfusion program 1 was used (Fig 7). In particular, type II collagen was produced only upon culture with BIT, with no major differences between static and dynamic samples, while type I collagen was not strongly induced by BIT (Fig 7a). This observation was confirmed by the densitometric quantification of WB data (Fig 7b), showing that no significant differences were found in the production of type I collagen between CTR and BIT samples in both static and dynamic conditions. Importantly, both in the presence and in the absence of BIT, perfusion induced a strong decrease in type I collagen synthesis compared to static culture (Fig 7).
(a) Representative WB analysis of type II and type I collagen after 21 days in static or dynamic conditions (program 1) in the absence (CTR) or in the presence of BIT. The positions of mature collagen chains (mature), unprocessed (pro) or processing intermediates of the procollagen containing the aminopropetide (pN) or the carboxypropetide (pC) are indicated. The upper band represents dimers (β) of collagen molecules. Actin bands are shown as a control for equivalent loading of the extracts. Please note that because type II collagen was relatively more abundantly produced in the presence of BIT, bands are smeared. (b) Quantification of type I collagen through the densitometric analysis of WB data. Total type I collagen (i.e. the unprocessed chains, the processing intermediates of the procollagen and the mature collagen chains) was normalized to actin. The values given in the dot plot represent single data points with mean (n = 3, a: p < 0.05).
Altogether, our results indicated that a stop in type I collagen expression specifically occurred in dynamic conditions. Based on this, we examined cell morphology and collagen expression at different time points (7, 14, and 21 days). Special attention was given to the cells enclosed in the neo-synthesized ECM in the scaffold core. In static conditions, HACs maintained a fibroblastic shape from day 7 to day 21 (Fig 8). By contrast, HACs changed morphology during dynamic culture. Specifically, a fibroblastic shape was observed at day 7, whereas a round morphology was observed at days 14 and 21. IHC revealed the presence of type II collagen in cell cytoplasm at all the three time points in both dynamic and static conditions. In static conditions, the presence of type I collagen was detected both in the pericellular matrix and in cell cytoplasm at all the analyzed time points. Differently, in dynamic conditions, type I collagen was detected in the pericellular matrix from day 7 to day 21, but it was found in cell cytoplasm only until day 7 (Fig 8), indicating that at later time points HACs were no longer synthetizing type I collagen.
Collagen sponges seeded with HACs were cultured in either static or dynamic conditions (program 1, n = 2) in the presence of BIT. At day 7 (D7), day 14 (D14), and day 21 (D21), IHC analyses were performed to localize type II and type I collagen. In dynamic conditions, note the absence of type I collagen in cell cytoplasm at day 14 and 21, as attested by the lack of brown staining (red arrows). Type II collagen synthesis was instead maintained during the whole culture, as demonstrated by cell cytoplasm staining (yellow arrows) from day 7 to 21 (scale bars 10 μm).
Finally, to evaluate the in vivo behavior of redifferentiated HACs and the stability of the neo-synthesized matrix built in the presence of BIT, the constructs were subcutaneously implanted in nude mice. After 6 weeks, the constructs maintained their structural integrity and were processed for IHC analysis. HE staining indicated that neo-synthesized ECM was more homogeneously distributed throughout the dynamic constructs in comparison with static constructs where ECM was preferentially deposited at the periphery (Fig 9). IHC analysis revealed accumulation of type II collagen in ECM and persistent synthesis in cell cytoplasm, whereas type I collagen was detected in ECM, but not in cell cytoplasm (Fig 9). These observations together indicated that the spatial distribution of ECM generated in vitro was maintained after 6 weeks in vivo and that chondrocytes were able to maintain their differentiation state after implantation.
Collagen sponges seeded with HACs were cultured for 21 days in static or dynamic conditions (program 2, n = 3) in the presence of BIT and then implanted into the subcutaneous pockets of nude mice. Representative pictures showing HE staining of the sponges after 6 weeks in vivo are reported in the upper panel. The lower panels show parallel sections of the scaffold core stained for type II and type I collagen by IHC (upper panel: scale bars 100 μm; lower panel: scale bars 10 μm).
Discussion
We explored here the combined influence of a bidirectional perfusion bioreactor and of an optimized protocol for the redifferentiation of HACs in clinical-grade collagen sponges. It is well-known that amplification of HACs induces dedifferentiation, resulting in the progressive increase in type I collagen at the expense of type II collagen expression [23]. We have previously reported that FI, besides its proliferative effect on HACs, also stimulates HAC dedifferentiation [7]. In accordance with these previously published data, the morphological changes and gene expression data reported in the present study confirmed that HACs underwent dedifferentiation upon amplification with FI.
The OPB prototype takes into account important features for clinical translation, such as the possibility to perform a streamlined process including cell seeding and construct maturation in a closed-loop chamber, suitability to scale up and scale out, automation and ease of use [11]. Previous works have shown that perfusion culture enhances cell access to oxygen and nutrients and homogenous ECM deposition in 3D scaffolds [9, 24]. Here, we applied a relatively high flow velocity in the OPB during the cell seeding phase to improve seeding efficiency, and then two different perfusion programs. In program 1, a constant perfusion was applied using a flow velocity of 100 μm/s that has been previously shown to be suitable to obtain stable oxygen tension and homogeneous matrix deposition in 3D foam scaffolds [9]. Also the flow velocities used in program 2 were selected on the basis of previous studies. Pazzano et al [25] demonstrated that perfusion at 1 μm/s stimulated matrix neo-synthesis in 3D scaffolds. Other studies [26, 27] have shown that low flow velocity (10 μm/s and 7 μm/s) is required during the first days to protect early matrix deposition in porous scaffolds and that type II collagen and proteoglycan synthesis can be further enhanced slowly increasing the velocity from 7 to 19 μm/s. Here, we did not observe major differences between the two perfusion programs. Indeed, both programs improved cell distribution and the quality and homogeneity of the neo-synthesized matrix, compared to static culture. This was particularly evident in the sponge core, where neo-synthesis of type II collagen-rich ECM occurred in dynamic, but not in static conditions.
In this study, we paid particular attention to the nature of the collagen in the neo-synthesized matrix. WB analyses showed that type II collagen, a typical marker of native cartilage [28], was produced both in static and in dynamic conditions. Undoubtedly, the combination of the FI and BIT cocktails proved to be crucial to amplify and re-induce HACs to produce cartilage proteins, as previously shown [7]. Indeed, we found that perfusion in the presence of 10% NCS alone was not sufficient to promote cartilage matrix synthesis. Additionally, in static conditions, although BIT induced type II collagen synthesis, the neo-synthesized matrix was restricted to the scaffold periphery. The homogeneous distribution of cartilaginous matrix was found only in dynamic constructs cultured with BIT, demonstrating that the combination of perfusion and BIT substantially improved the homogeneous reconstruction of cartilage in collagen sponges.
We also demonstrated the beneficial influence of perfusion on the decrease in type I collagen synthesis. Indeed, our results revealed that HACs entered a redifferentiation program towards cartilage matrix production upon perfusion culture. Specifically, HACs initially maintained a dedifferentiated transient phenotype in dynamic conditions, as illustrated by their fibroblastic morphology at day 7. At this stage, most fibroblastic cells stained for both type I and type II collagen, suggesting the expression of a transient phenotype. At the same time, we found type I, but not type II collagen, in the matrix surrounding fibroblastic cells. These observations indicate that the dedifferentiated HACs were in an early redifferentiation phase during the first week of dynamic culture and that they started to redifferentiate only afterwards. This was confirmed by observations at day 14 and day 21 showing round cells and the presence of type II collagen in both ECM and cell cytoplasm, indicating that type II collagen synthesis was sustained during perfusion culture. In contrast, the presence of type I collagen became restricted to the neo-synthesized matrix, indicating that HACs were no longer actively producing type I collagen. Accordingly, precursor forms of type I collagen were hardly detectable by WB after 21 days of perfusion. Altogether, these observations demonstrate that perfusion stimulates the construction of a neo-matrix that matures over time with type II collagen, at the expense of type I collagen. This result is particularly striking considering the pathological origin of the articular chondrocytes used in this study, since the ability of HAC from OA joints to redifferentiate has been found to be impaired in other culture conditions [29]. Our findings are consistent with other studies showing that perfusion inhibits type I collagen expression in human chondrocytes cultured in pellets [30] and in cartilage explants [31]. The molecular mechanisms underlying the inhibitory effect of perfusion on type I collagen in chondrocytes are still unknown. Nevertheless, it is known that perfusion exerts mechanical forces, such as fluid shear stress [24], and that the expression of several ECM proteins, including type I collagen, is sensitive to mechanical forces in cartilage [32]. Thus, we can hypothesize that the fluid flow perfused using the OPB may have mechanically stimulated the chondrocytes seeded within the collagen sponges leading to a reduction in type I collagen expression. The BIT cocktail has also been found to inhibit, to some extent, type I collagen expression in human dedifferentiated chondrocytes [8, 33, 34]. However, the strong decrease in type I collagen seen in the sponges cultivated without BIT in the OPB indicates that perfusion was the main determinant of the type I collagen inhibition observed in our study.
Although the stability of the neo-cartilage and of the chondrocyte phenotype observed after 6 weeks in the nude mouse model is very encouraging, pre-clinical trials with long-term implantation in cartilage lesions in larger animals are required to test mechanical properties and integration of the implant. Nevertheless, our results already demonstrate the value of a multi-factorial approach combining HACs from osteoarthritic joints, clinical-grade collagen scaffolds, BIT cocktail, and perfusion culture. This strategy allows to achieve a high degree of redifferentiation in dedifferentiated chondrocyte, not only by inducing the specific production and homogeneous distribution of hyaline matrix, but also by inhibiting type I collagen synthesis. This result is particularly relevant since it indicates that such a multi-factorial approach minimizes the risk of producing fibrocartilage, even when osteoarthritic chondrocytes are used. Remarkably, special efforts were made to develop an approach employing clinical-grade growth factors and scaffolds which, combined with the intrinsic features of the OPB and its compatibility with GMP requirements, can be easily translated into the clinical practice. Lastly, since articular cartilage is chronically hypoxic and we have shown that hypoxia combined with BMP-2 favors the redifferentiation of human chondrocytes cultured in monolayer [35] or in collagen sponges [36, 37], it would be pertinent to investigate if hypoxic conditions can further improve the outcomes of our multi-factorial approach.
Supporting Information
S1 Fig. ECM distribution and cellular localization of type II and type I collagen after culture in dynamic conditions (program 1).
Pictures of the inner core of the scaffolds showing HE, type II collagen and type I collagen staining of HACs from 4 donors cultured for 21 days in dynamic conditions using program 1 (scale bars 10 μm). Red arrows indicate cellular areas negative for type I collagen, demonstrating that HACs cultured in dynamic conditions are not synthesizing this type of collagen.
https://doi.org/10.1371/journal.pone.0161479.s001
(TIF)
S2 Fig. ECM distribution and cellular localization of type II and type I collagen after culture in dynamic conditions (program 2).
Pictures of the inner core of the scaffolds showing HE, type II collagen and type I collagen staining of HACs from 6 donors cultured for 21 days in dynamic conditions using program 2 (scale bars 10 μm). Red arrows indicate cellular areas negative for type I collagen, indicating that HACs cultured in dynamic conditions are not producing this type of collagen.
https://doi.org/10.1371/journal.pone.0161479.s002
(TIF)
Acknowledgments
We thank the technical facilities of UMS 3444 (BioSciences Gerland-Lyon Sud) for performing the quantitative PCR analyses.
Author Contributions
- Conceptualization: NM SL SR MM FMG.
- Formal analysis: NM SL MM FMG.
- Funding acquisition: MM FMG.
- Investigation: NM SL GT ABL MP.
- Methodology: NM SL GT MM FMG.
- Project administration: MM FMG.
- Resources: MM FMG.
- Supervision: MM FMG.
- Visualization: NM SL MM FMG.
- Writing – original draft: NM SL MM FMG.
- Writing – review & editing: NM SL MM FMG.
References
- 1. Hangody L, Fules P. Autologous osteochondral mosaicplasty for the treatment of full-thickness defects of weight-bearing joints: ten years of experimental and clinical experience. J Bone Joint Surg Am. 2003;85-A Suppl 2: 25–32. pmid:12721342
- 2. Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grontvedt T, Solheim E, et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am. 2004;86-A: 455–464. pmid:14996869
- 3. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331: 889–895. pmid:8078550
- 4. Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan AM, Briggs TW, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. J Bone Joint Surg Br. 2005;87: 640–645. pmid:15855365
- 5. Roberts S, Menage J, Sandell LJ, Evans EH, Richardson JB. Immunohistochemical study of collagen types I and II and procollagen IIA in human cartilage repair tissue following autologous chondrocyte implantation. Knee. 2009;16: 398–404. pmid:19269183
- 6. Horas U, Pelinkovic D, Herr G, Aigner T, Schnettler R. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. J Bone Joint Surg Am. 2003;85-A: 185–192. pmid:12571292
- 7. Claus S, Mayer N, Aubert-Foucher E, Chajra H, Perrier-Groult E, Lafont J, et al. Cartilage-characteristic matrix reconstruction by sequential addition of soluble factors during expansion of human articular chondrocytes and their cultivation in collagen sponges. Tissue engineering Part C, Methods. 2012;18: 104–112. pmid:21933021
- 8. Liu G, Kawaguchi H, Ogasawara T, Asawa Y, Kishimoto J, Takahashi T, et al. Optimal combination of soluble factors for tissue engineering of permanent cartilage from cultured human chondrocytes. J Biol Chem. 2007;282: 20407–20415. pmid:17493933
- 9. Wendt D, Stroebel S, Jakob M, John GT, Martin I. Uniform tissues engineered by seeding and culturing cells in 3D scaffolds under perfusion at defined oxygen tensions. Biorheology. 2006;43: 481–488. pmid:16912419
- 10. Santoro R, Olivares AL, Brans G, Wirz D, Longinotti C, Lacroix D, et al. Bioreactor based engineering of large-scale human cartilage grafts for joint resurfacing. Biomaterials. 2010;31: 8946–8952. pmid:20800280
- 11.
Moretti MG, Freed, L.E., Langer R., inventorOscillating Cell Culture Bioreactor, Pub. No.: US2010/0297233 A1Nov. 25, 2010.
- 12. Cheng M, Moretti M, Engelmayr GC, Freed LE. Insulin-like growth factor-I and slow, bi-directional perfusion enhance the formation of tissue-engineered cardiac grafts. Tissue Eng Part A. 2009;15: 645–653. pmid:18759675
- 13. Valonen PK, Moutos FT, Kusanagi A, Moretti MG, Diekman BO, Welter JF, et al. In vitro generation of mechanically functional cartilage grafts based on adult human stem cells and 3D-woven poly(epsilon-caprolactone) scaffolds. Biomaterials. 2010;31: 2193–2200. pmid:20034665
- 14. Hautier A, Salentey V, Aubert-Foucher E, Bougault C, Beauchef G, Ronziere MC, et al. Bone morphogenetic protein-2 stimulates chondrogenic expression in human nasal chondrocytes expanded in vitro. Growth Factors. 2008;26: 201–211. pmid:18720162
- 15. Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F. Functions of transforming growth factor-beta family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. J Biol Chem. 2002;277: 33545–33558. pmid:12082094
- 16. Martin I, Jakob M, Schafer D, Dick W, Spagnoli G, Heberer M. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage. 2001;9: 112–118. pmid:11237658
- 17. Le Guellec D, Mallein-Gerin F, Treilleux I, Bonaventure J, Peysson P, Herbage D. Localization of the expression of type I, II and III collagen genes in human normal and hypochondrogenesis cartilage canals. Histochem J. 1994;26: 695–704. pmid:7843983
- 18. Dell'Accio F, De Bari C, Luyten FP. Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis and rheumatism. 2001;44: 1608–1619. pmid:11465712
- 19. Sabatino MA, Santoro R, Gueven S, Jaquiery C, Wendt DJ, Martin I, et al. Cartilage graft engineering by co-culturing primary human articular chondrocytes with human bone marrow stromal cells. Journal of tissue engineering and regenerative medicine. 2015;9: 1394–1403. pmid:23225781
- 20. Oliveira JT, Santos TC, Martins L, Silva MA, Marques AP, Castro AG, et al. Performance of new gellan gum hydrogels combined with human articular chondrocytes for cartilage regeneration when subcutaneously implanted in nude mice. Journal of tissue engineering and regenerative medicine. 2009;3: 493–500. pmid:19598145
- 21. Colombini A, Lopa S, Ceriani C, Lovati AB, Croiset SJ, Di Giancamillo A, et al. In vitro characterization and in vivo behavior of human nucleus pulposus and annulus fibrosus cells in clinical-grade fibrin and collagen-enriched fibrin gels. Tissue engineering Part A. 2015;21: 793–802. pmid:25236589
- 22. Lopa S, Piraino F, Kemp RJ, Di Caro C, Lovati AB, Di Giancamillo A, et al. Fabrication of multi-well chips for spheroid cultures and implantable constructs through rapid prototyping techniques. Biotechnology and bioengineering. 2015;112: 1457–1471. pmid:25678107
- 23. von der Mark K, Gauss V, von der Mark H, Muller P. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature. 1977;267: 531–532. pmid:559947
- 24. Moretti M, Freed LE, Padera RF, Lagana K, Boschetti F, Raimondi MT. An integrated experimental-computational approach for the study of engineered cartilage constructs subjected to combined regimens of hydrostatic pressure and interstitial perfusion. Biomed Mater Eng. 2008;18: 273–278. pmid:19065033
- 25. Pazzano D, Mercier KA, Moran JM, Fong SS, DiBiasio DD, Rulfs JX, et al. Comparison of chondrogensis in static and perfused bioreactor culture. Biotechnol Prog. 2000;16: 893–896. pmid:11027186
- 26. Davisson T, Sah RL, Ratcliffe A. Perfusion increases cell content and matrix synthesis in chondrocyte three-dimensional cultures. Tissue engineering. 2002;8: 807–816. pmid:12459059
- 27. Shahin K, Doran PM. Strategies for enhancing the accumulation and retention of extracellular matrix in tissue-engineered cartilage cultured in bioreactors. PloS one. 2011;6: e23119. pmid:21858004
- 28. Gouttenoire J, Valcourt U, Ronziere MC, Aubert-Foucher E, Mallein-Gerin F, Herbage D. Modulation of collagen synthesis in normal and osteoarthritic cartilage. Biorheology. 2004;41: 535–542. pmid:15299284
- 29. Yang KG, Saris DB, Geuze RE, van Rijen MH, van der Helm YJ, Verbout AJ, et al. Altered in vitro chondrogenic properties of chondrocytes harvested from unaffected cartilage in osteoarthritic joints. Osteoarthritis Cartilage. 2006;14: 561–570. pmid:16735197
- 30. Raimondi MT, Bonacina E, Candiani G, Lagana M, Rolando E, Talo G, et al. Comparative chondrogenesis of human cells in a 3D integrated experimental-computational mechanobiology model. Biomech Model Mechanobiol. 2011;10: 259–268. pmid:20549292
- 31. Pei M, Solchaga LA, Seidel J, Zeng L, Vunjak-Novakovic G, Caplan AI, et al. Bioreactors mediate the effectiveness of tissue engineering scaffolds. FASEB J. 2002;16: 1691–1694. pmid:12207008
- 32. Fitzgerald JB, Jin M, Chai DH, Siparsky P, Fanning P, Grodzinsky AJ. Shear- and compression-induced chondrocyte transcription requires MAPK activation in cartilage explants. J Biol Chem. 2008;283: 6735–6743. pmid:18086670
- 33. Asawa Y, Ogasawara T, Takahashi T, Yamaoka H, Nishizawa S, Matsudaira K, et al. Aptitude of auricular and nasoseptal chondrocytes cultured under a monolayer or three-dimensional condition for cartilage tissue engineering. Tissue Eng Part A. 2009;15: 1109–1118. pmid:19061429
- 34. Yamaoka H, Tanaka Y, Nishizawa S, Asawa Y, Takato T, Hoshi K. The application of atelocollagen gel in combination with porous scaffolds for cartilage tissue engineering and its suitable conditions. J Biomed Mater Res A. 2010;93: 123–132. pmid:19536835
- 35. Lafont JE, Poujade FA, Pasdeloup M, Neyret P, Mallein-Gerin F. Hypoxia potentiates the BMP-2 driven COL2A1 stimulation in human articular chondrocytes via p38 MAPK. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. 2016;24: 856–867. pmid:26708156
- 36. Legendre F, Ollitrault D, Hervieu M, Bauge C, Maneix L, Goux D, et al. Enhanced hyaline cartilage matrix synthesis in collagen sponge scaffolds by using siRNA to stabilize chondrocytes phenotype cultured with bone morphogenetic protein-2 under hypoxia. Tissue engineering Part C, Methods. 2013;19: 550–567. pmid:23270543
- 37. Ollitrault D, Legendre F, Drougard C, Briand M, Benateau H, Goux D, et al. BMP-2, hypoxia, and COL1A1/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes. Tissue engineering Part C, Methods. 2015;21: 133–147. pmid:24957638